Both heparin and bivalirudin are antithrombotic agents.
They are administered to patients in the cardiac catheter
lab during their emergency treatment for STEMI. Both are
in widespread and routine clinical use around the world.
There is debate as to whether one has advantage over the
other. HEAT-PPCI was a randomised controlled trial
(RCT) designed to inform this debate.